Modified release @entity21819 in the treatment of XXXX .

@entity1 @entity508 @entity75 @entity21819
A 6-week study of a modified release formulation of @entity21819 designed for once daily administration was performed in 27 @entity1 with @entity508 due to @entity75 . The dosage of @entity21819 used ranged from 6 to 18 mg/day. At the start of the study all @entity1 had at least moderate @entity508 and 20 (74%) @entity1 had severe or very severe @entity508 . All had a decrease in muscle strength. After 1 week of treatment 22 (81%) @entity1 showed improvement in overall spastic state and, after 6 weeks, all 27 @entity1 had improved. At the end of treatment 25 (93%) @entity1 showed an improvement in overall disability. The drug was well tolerated. Side-effects were reported in only four @entity1 , and these were minor and mostly mild. @entity21819 had no clinically important effects on blood pressure, heart rate, body weight or laboratory values. Overall, once daily treatment with modified release @entity21819 is well tolerated and gives good clinical efficacy in @entity1 with @entity508 .
